Delta-Opioid Receptor

Total Page:16

File Type:pdf, Size:1020Kb

Delta-Opioid Receptor Structural Evolution of a Bifunctional Mu-Opioid Receptor (MOR)/Delta-Opioid Receptor (DOR) Peptidomimetic as Nonaddictive Opioid Analgesics by Sean P. Henry A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Medicinal Chemistry) in the University of Michigan 2019 Doctoral Committee: Professor Henry I. Mosberg, Chair Professor Scott D. Larsen Associate Professor Peter J. H. Scott Professor John. R. Traynor Sean P. Henry [email protected] ORCID iD: 0000-0002-4405-062X © Sean P. Henry 2019 Acknowledgements I would first and foremost like to thank the Lord my God. Without His grace, I would not have been able to enter this PhD program, nor would I have been able to complete the research presented herein. Without His guidance, I would not have been able to find my calling: the synthesis and development of novel pharmaceuticals. For that, I am eternally grateful. To my family back home, Timothy Henry, Brenda Skinner, Kevin Henry, and Joan Henry, thank you all for supporting me and blessing me with all you know. I love you all and hope to give to others what you have given to me. Timothy, you have been a source of inspiration, for both your love of science and for your enduring patience. May you rest in peace. Dr. Henry Mosberg, your guidance and wisdom throughout my time here has thoroughly enriched my understanding of medicine and drug design. Without your efforts, I would not have been able to complete this program and the quality of our work would have suffered. For that, I thank you. I also would like to thank the members of my committee: Dr. Scott Larsen, Dr. Peter Scott, and Dr. John Traynor. Your insights have broadened my horizons and have contributed greatly to my development as a scientist. I would like to thank Dr. Nicholas Griggs, Thomas Fernandez, and Dr. Jess Anand for acquiring the in vitro data presented herein. Without these data, this project would only be an exercise in organic synthesis and the contributions to our understanding of the opioid receptors would be lost. I would also like to thank Bryan Sears, whose studious efforts in acquiring our in vivo data have proven invaluable for the development of these ligands. Finally, I would like Kate Kojiro, whose knowledge in the laboratory have streamlined my work by no small means. ii To Dr. Larisa Yeomans and your husband Matthew Cruz, your kindness and grace have always been warm and welcoming. You have always been there when I needed you, and for that, I count among my dearest of friends. To my coworkers Dr. Tanpreet Kaur, Dr. Deanna Montgomery, Dr. Tony Nastase, and Jay Kim, your levity and companionship have lightened many a rainy day. The completion of this dissertation would have been much less wholesome without you all. Finally, I would like to thank my friends from both GCF and 2:42. Your friendship has contributed to my growth in innumerable ways and I will never forget the good times that we have had together. iii TABLE OF CONTENTS Acknowledgments ii List of Figures vi List of Schemes viii List of Tables ix List of Abbreviations xi Abstract xv Chapter 1: On Opioids 1 1.1 The Opioid Epidemic 1 1.2 The Opioid Receptors and their Effects 2 1.3 Bifunctional MOR/DOR Ligands 4 1.4 From the Opioid Peptides to AAH8 6 1.5 Project Overview 10 Chapter 2: Breaking the THQ Core 14 2.1 Introduction 14 2.2 Results 15 2.3 Discussion and Conclusions 24 2.4 Experimental 29 Chapter 3: Further Derivatization of the Aromatic Core 63 3.1 Introduction 63 3.2 Results 64 3.3 Discussion and Conclusion 73 3.4 Experimental 78 iv Chapter 4: Amine Pendants as MOR Pharmacophores with Improved Stability 100 4.1 Introduction 100 4.2 Results 101 4.3 Discussion and Conclusion 110 4.4 Experimental 114 Chapter 5: Discovery of Aromatic-Amine Pharmacophore 133 5.1 Introduction 133 5.2 Results 135 5.3 Discussion and Conclusions 146 5.4 Experimental 154 Chapter 6: Aromatic-Amine Pharmacophore Enables Removal of Aromatic Core 183 6.1 Introduction 183 6.2 Results 193 6.3 Discussion and Conclusions 183 6.4 Experimental 198 Chapter 7: Aliphatic Heterocycles as Novel Core Elements 216 7.1 Introduction 216 7.2 Results 217 7.3 Discussion and Conclusions 223 7.4 Experimental 226 Chapter 8: Conclusions and Future Directions 246 8.1 Conclusions 246 8.2 Future Directions 251 Appendix 258 References 259 v List of Figures Figure 1: Notable small molecules that exhibit a MOR-agonist/DOR-antagonist profile. 5 Figure 2: General SAR of the opioid peptides. 7 Figure 3: Structural evolution of the endogenous peptide Met-enkephalin into the lead peptidomimetic KSKPP1E. 9 Figure 4: Diversification strategies employed to explore the SAR of KSKPP1E. 10 Figure 5: Normalized metabolic half-life of peptidomimetics that contain a THQ core or similar bicyclic core structure. 11 Figure 6: Known metabolites of KSKPP1E from MLM. 12 Figure 7: Pharmacophore and linker elements of KSKPP1E and our initial monocyclic core series. 15 Figure 8: Molecular modeling of analogue 70 at MOR. 24 Figure 9: Further derivatization of compounds 60 and 70. 64 Figure 10: Proposed CYP450 reaction mechanism on analogues 70, 106, 107, and 114. 77 Figure 11: Design path leading to stable peptidomimetics with basic amine pendants. 101 Figure 12: Antinociceptive activity of analogues 70, 127-128, and 131-134 using the acetic acid stretch assay. 109 Figure 13: Stability ratio of analogues 127-128 and 131-136 against their cLogP. 112 Figure 14: Design of amine pendant analogues with different aromatic core modifications. 135 Figure 15: Molecular docking of superagonist 168 at the three opioid receptors. 145 Figure 16: Antinociceptive activity of 132 and analogues 168, 172, 176, and 180 using the AASA. 146 Figure 17: Literature structures that are close to our discovered aromatic-amine pharmacophore outside of our previously reported peptidomimetic series. 153 Figure 18: Design of analogues possessing greater simplification of core elements. 184 Figure 19: Molecular docking of analogue 193 at the three opioid receptors. 192 vi Figure 20: Antinociceptive activity of the 168 and analogues 193-194, and 197-200 using the AASA. 193 Figure 21: Conversion of aromatic core peptidomimetic to cyclic aliphatic core peptidomimetics. 217 Figure 22: Summary of results from Chapters 2 and 3. 247 Figure 23: Summary of results from Chapters 4 and 5. 248 Figure 24: Summary of results from Chapter 6. 250 Figure 25: Summary of Results from Chapter 7. 251 Figure 26: General design scope upon which further analogues may be developed. 252 Figure 27: Proposed analogues to be synthesized that modify the aromatic-amine pharmacophore. 253 Figure 28: Proposed peptide derivatives of analogues 199 and 200. 253 Figure 29: Proposed analogues that modify the aromatic core. 254 Figure 30: Rigid cyclic core derivatives akin to analogues 196-197. 255 Figure 26: Proposed derivatives of the cyclic aliphatic analogue 229. 256 vii List of Schemes Scheme 1: Synthesis of AAH8. 13 Scheme 2: Synthesis of Substituted Monocyclic Core Analogues 59-74. 16 Scheme 3: Synthesis of Analogues 101-104. 65 Scheme 4: Synthesis of Analogue 105. 66 Scheme 5: Synthesis of Analogues 106-107. 66 Scheme 6: Synthesis of Analogue 114. 67 Scheme 7: Synthesis of Amine or Amide Pendant Analogues Containing an Ethyl Ether. 102 Scheme 8: Synthesis of aromatic core analogues containing amine pendants to produce SAR matrices. 136 Scheme 9: Synthesis of Analogues 193-197. 185 Scheme 10: Synthesis of Peptide Core Analogues 198-200. 186 Scheme 11: Synthesis of Analogues 224-231. 219 viii List of Tables Table 1: The opioid receptors, their location, and their phenotypic effects on activation. 2 Table 2: Binding affinity of the benzylic core compounds at MOR, DOR, and KOR. 19 Table 3: Potency and efficacy of benzylic core compounds at MOR, DOR, and KOR. 20 Table 4: Metabolic stability of benzylic core compounds in MLM. 22 Table 5: Binding affinity of 2nd generation benzylic derivatives at MOR, DOR, and KOR. 68 Table 6: Potency and efficacy of 2nd generation benzylic derivatives at MOR, DOR, and KOR. 69 Table 7: Binding affinity of 2nd generation aromatic derivatives at MOR, DOR, and KOR. 70 Table 8: Potency and efficacy of 2nd generation aromatic derivatives at MOR, DOR, and KOR. 71 Table 9: Metabolic stability of 2nd generation benzylic derivatives in MLM. 72 Table 10: Metabolic stability of 2nd generation aromatic derivatives in MLM. 73 Table 11: Binding affinity of amine or amide pendant analogues at MOR, DOR, and KOR. 104 Table 12: Efficacy and potency of amine or amide pendant analogues at MOR, DOR, and KOR. 106 Table 13: Metabolic stability of amine or amide pendant analogues in MLM. 107 Table 14: Binding affinity matrix (Ki (nM)) of amine analogues of benzylic core structures from Chapter 2 at MOR and DOR. 138 Table 15: Binding affinity (Ki (nM)) matrices of amine analogues of benzylic core structures from Chapter 2 at KOR and their selectivity. 140 Table 16: Potency matrices of amine analogues of previously reported benzylic core structures from Chapter 2 at MOR, DOR, and KOR. 141 Table 17: Efficacy matrices of amine analogues of previously reported benzylic core structures from Chapter 2 at MOR, DOR, and KOR. 143 Table 18: Metabolic stability matrix of amine analogues of previously reported benzylic core structures from Chapter 2. 144 Table 19: Binding affinity of simple core compounds at MOR, DOR, and KOR. 188 Table 20: Efficacy and potency of simple core compounds at MOR, DOR, and KOR.
Recommended publications
  • Evaluation of in Silico Approach for Prediction of Presence of Opioid Peptides in Wheat
    Evaluation of in silico approach for prediction of presence of opioid peptides in wheat This is the Accepted version of the following publication Garg, Swati, Apostolopoulos, Vasso, Nurgali, Kulmira and Mishra, Vijay Kumar (2018) Evaluation of in silico approach for prediction of presence of opioid peptides in wheat. Journal of Functional Foods, 41. 34 - 40. ISSN 1756-4646 The publisher’s official version can be found at https://www.sciencedirect.com/science/article/pii/S1756464617307454 Note that access to this version may require subscription. Downloaded from VU Research Repository https://vuir.vu.edu.au/36577/ 1 1 Evaluation of in silico approach for prediction of presence of opioid peptides in wheat 2 gluten 3 Abstract 4 Opioid like morphine and codeine are used for the management of pain, but are associated 5 with serious side-effects limiting their use. Wheat gluten proteins were assessed for the 6 presence of opioid peptides on the basis of tyrosine and proline within their sequence. Eleven 7 peptides were identified and occurrence of predicted sequences or their structural motifs were 8 analysed using BIOPEP database and ranked using PeptideRanker. Based on higher peptide 9 ranking, three sequences YPG, YYPG and YIPP were selected for determination of opioid 10 activity by cAMP assay against µ and κ opioid receptors. Three peptides inhibited the 11 production of cAMP to varied degree with EC50 values of YPG, YYPG and YIPP were 5.3 12 mM, 1.5 mM and 2.9 mM for µ-opioid receptor, and 1.9 mM, 1.2 mM and 3.2 mM for κ- 13 opioid receptor, respectively.
    [Show full text]
  • Ong Edmund W 201703 Phd.Pdf (5.844Mb)
    INVESTIGATING THE EFFECTS OF PROLONGED MU OPIOID RECEPTOR ACTIVATION UPON OPIOID RECEPTOR HETEROMERIZATION by Edmund Wing Ong A thesis submitted to the Graduate Program in Pharmacology & Toxicology in the Department of Biomedical and Molecular Sciences In conformity with the requirements for the degree of Doctor of Philosophy Queen’s University Kingston, Ontario, Canada March, 2017 Copyright © Edmund Wing Ong, 2017 Abstract Opioid receptors are the sites of action for morphine and most other clinically-used opioid drugs. Abundant evidence now demonstrates that different opioid receptor types can physically associate to form heteromers. Owing to their constituent monomers’ involvement in analgesia, mu/delta opioid receptor (M/DOR) heteromers have been a particular focus of attention. Understandings of the physiological relevance of M/DOR formation remain limited in large part due to the reliance of existing M/DOR findings upon contrived heterologous systems. This thesis investigated the physiological relevance of M/DOR generation following prolonged MOR activation. To address M/DOR in endogenous tissues, suitable model systems and experimental tools were established. This included a viable dorsal root ganglion (DRG) neuron primary culture model, antisera specifically directed against M/DOR, a quantitative immunofluorescence colocalizational analysis method, and a floxed-Stop, FLAG-tagged DOR conditional knock-in mouse model. The development and implementation of such techniques make it possible to conduct experiments addressing the nature of M/DOR heteromers in systems with compelling physiological relevance. Seeking to both reinforce and extend existing findings from heterologous systems, it was first necessary to demonstrate the existence of M/DOR heteromers. Using antibodies directed against M/DOR itself as well as constituent monomers, M/DOR heteromers were identified in endogenous tissues and demonstrated to increase in abundance following prolonged mu opioid receptor (MOR) activation by morphine.
    [Show full text]
  • Example of a Scientific Poster
    Janet Robishaw, PhD Senior Associate Dean for Research Chair and Professor, Biomedical Science Florida Atlantic University Charles E. Schmidt College of Medicine Disclosures and Conflicts • I have no actual or potential conflict of interest in relation to this program/presentation. • Research support: Robishaw, MPI Robishaw, MPI R01 DA044015 R01 HL134015 Genetic Predictors of Opioid Addiction Genetic Heterogeneity of Sleep Apnea 2017-2022 2016-2021 Robishaw, PI Robishaw, MPI R01 GM114665 R01 GM111913 Novel Aspects of Golf Signaling GPCR Variants in Complex Diseases 2015-2019 2015-2019 Learning Objectives 1. Review the scope and root cause of opioid use disorder 2. Discuss the effects of opioid medications on the brain and body 3. Stress the importance of clinical judgement and discovery to address the opioid crisis 4. Highlight the clinical implications between opioid use disorder and heroin abuse Two Endemic Problems Chronic Pain Opioid Use Disorder Debilitating disorder Chronic, relapsing disorder 100 million Americans 2 million Americans Costs $630 billion dollars per year Costs $80 billion per year #1 presenting complaint to doctors # 1 cause of accidental death #1 reason for lost productivity #1 driver of heroin epidemic #1 treatment –opioid medications ? treatment Pain Relief and “Addiction” Share A Common Mechanism of Action m-Opioid Receptor Brain Regions Involved in Pleasure and Reward Increase dopamine release Brain Regions Involved in Pain Perception Brainstem Involved in Respiratory Control Spinal Cord Involved in Pain Transmission Prevent ascending transmission Turn on descending inhibitory systems These receptors are dispersed Inhibit peripheral nocioceptors throughout the body, thereby accounting for their differential Body effects on pain and reward paths.
    [Show full text]
  • Biased Versus Partial Agonism in the Search for Safer Opioid Analgesics
    molecules Review Biased versus Partial Agonism in the Search for Safer Opioid Analgesics Joaquim Azevedo Neto 1 , Anna Costanzini 2 , Roberto De Giorgio 2 , David G. Lambert 3 , Chiara Ruzza 1,4,* and Girolamo Calò 1 1 Department of Biomedical and Specialty Surgical Sciences, Section of Pharmacology, University of Ferrara, 44121 Ferrara, Italy; [email protected] (J.A.N.); [email protected] (G.C.) 2 Department of Morphology, Surgery, Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] (A.C.); [email protected] (R.D.G.) 3 Department of Cardiovascular Sciences, Anesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 7RH, UK; [email protected] 4 Technopole of Ferrara, LTTA Laboratory for Advanced Therapies, 44122 Ferrara, Italy * Correspondence: [email protected] Academic Editor: Helmut Schmidhammer Received: 23 July 2020; Accepted: 23 August 2020; Published: 25 August 2020 Abstract: Opioids such as morphine—acting at the mu opioid receptor—are the mainstay for treatment of moderate to severe pain and have good efficacy in these indications. However, these drugs produce a plethora of unwanted adverse effects including respiratory depression, constipation, immune suppression and with prolonged treatment, tolerance, dependence and abuse liability. Studies in β-arrestin 2 gene knockout (βarr2( / )) animals indicate that morphine analgesia is potentiated − − while side effects are reduced, suggesting that drugs biased away from arrestin may manifest with a reduced-side-effect profile. However, there is controversy in this area with improvement of morphine-induced constipation and reduced respiratory effects in βarr2( / ) mice. Moreover, − − studies performed with mice genetically engineered with G-protein-biased mu receptors suggested increased sensitivity of these animals to both analgesic actions and side effects of opioid drugs.
    [Show full text]
  • Federal Register/Vol. 85, No. 36/Monday, February 24, 2020
    10466 Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices Controlled substance Drug code Schedule Alphamethadol ................................................................................................................................................................. 9605 I Benzethidine .................................................................................................................................................................... 9606 I Betacetylmethadol ........................................................................................................................................................... 9607 I Clonitazene ...................................................................................................................................................................... 9612 I Diampromide ................................................................................................................................................................... 9615 I Diethylthiambutene .......................................................................................................................................................... 9616 I Dimethylthiambutene ....................................................................................................................................................... 9619 I Ketobemidone .................................................................................................................................................................
    [Show full text]
  • Medications to Treat Opioid Use Disorder Research Report
    Research Report Revised Junio 2018 Medications to Treat Opioid Use Disorder Research Report Table of Contents Medications to Treat Opioid Use Disorder Research Report Overview How do medications to treat opioid use disorder work? How effective are medications to treat opioid use disorder? What are misconceptions about maintenance treatment? What is the treatment need versus the diversion risk for opioid use disorder treatment? What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? How is opioid use disorder treated in the criminal justice system? Is medication to treat opioid use disorder available in the military? What treatment is available for pregnant mothers and their babies? How much does opioid treatment cost? Is naloxone accessible? References Page 1 Medications to Treat Opioid Use Disorder Research Report Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone. Overview An estimated 1.4 million people in the United States had a substance use disorder related to prescription opioids in 2019.1 However, only a fraction of people with prescription opioid use disorders receive tailored treatment (22 percent in 2019).1 Overdose deaths involving prescription opioids more than quadrupled from 1999 through 2016 followed by significant declines reported in both 2018 and 2019.2,3 Besides overdose, consequences of the opioid crisis include a rising incidence of infants born dependent on opioids because their mothers used these substances during pregnancy4,5 and increased spread of infectious diseases, including HIV and hepatitis C (HCV), as was seen in 2015 in southern Indiana.6 Effective prevention and treatment strategies exist for opioid misuse and use disorder but are highly underutilized across the United States.
    [Show full text]
  • Summary Analgesics Dec2019
    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
    [Show full text]
  • Opioid Overdose – Use of Naloxone
    CHAPTER: 41.3.1 Page 1 of 4 NEW ORLEANS POLICE DEPARTMENT OPERATIONS MANUAL CHAPTER: 41.3.1 TITLE: OPIOID OVERDOSE – USE OF NALOXONE EFFECTIVE: 10/22/2017 REVISED: 06/24/2018 PURPOSE The purpose of this policy is to set forth guidelines with respect to the appropriate field administration of Naloxone (Narcan) kits by members of New Orleans Police Department in suspected opiate / opioid overdose incidents. POLICY STATEMENT 1. Commissioned members of the NOPD are often the first emergency responders to the scene of a medical, suspected medical and overdose incident. Recognizing this, the NOPD has adopted this Chapter with the following goals: (a) To provide a framework for training in the field use of Naloxone, (b) To provide a framework on the proper field administration of Naloxone, and (c) To facilitate life-saving intervention in suspected opiate / opioid overdose incidents where NOPD officers are the first to arrive on the scene. 2. All commissioned and/or civilian members who have been trained in the use and administration of the department’s Naloxone nasal administration kits for suspected opiate / opioid overdose incidents are authorized to carry, use and administer the kits. 3. All members responding to medical calls, including suspected opioid overdoses, shall use universal precautions. DEFINITIONS: Definitions related to this Chapter include: Administration—Nasal administration of approved Naloxone 2mg kits with atomizer; 1mg (1/2 dose) to be administered in each nostril. Naloxone—A narcotic analgesic antagonist, used in the reversal of acute narcotic analgesic respiratory depression. Naloxone is effectively an antidote to opioid overdose and may completely reverse the effects of an opioid overdose if administered in time.
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • 1 Title Page Pharmacological Comparison of Mitragynine and 7
    JPET Fast Forward. Published on December 31, 2020 as DOI: 10.1124/jpet.120.000189 This article has not been copyedited and formatted. The final version may differ from this version. JPET-AR-2020-000189R1: Obeng et al. Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for Mu-Opioid Receptor and Morphine-Like Discriminative-Stimulus Effects in Rats. Title Page Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for Mu-Opioid Receptor and Opioid-Like Behavioral Effects in Rats Samuel Obeng1,2,#, Jenny L. Wilkerson1,#, Francisco León2, Morgan E. Reeves1, Luis F. Restrepo1, Lea R. Gamez-Jimenez1, Avi Patel1, Anna E. Pennington1, Victoria A. Taylor1, Nicholas P. Ho1, Tobias Braun1, John D. Fortner2, Morgan L. Crowley2, Morgan R. Williamson1, Victoria L.C. Pallares1, Marco Mottinelli2, Carolina Lopera-Londoño2, Christopher R. McCurdy2, Lance R. McMahon1, and Takato Hiranita1* Downloaded from Departments of Pharmacodynamics1 and Medicinal Chemistry2, College of Pharmacy, University of Florida jpet.aspetjournals.org #These authors contributed equally Recommended section: Behavioral Pharmacology at ASPET Journals on September 29, 2021 Correspondence: *Takato Hiranita, Ph.D. Department of Pharmacodynamics, College of Pharmacy, University of Florida 1345 Center Drive, Gainesville, FL 32610 Email: [email protected] Phone: +1.352.294.5411 Fax: +1.352.273.7705 Keywords: kratom, mitragynine, 7-hydroxymitragynine, morphine, opioid, discriminative stimulus Conflicts of Interests or Disclaimers: None Manuscript statistics: Number of text pages: 56 Number of tables: 7 Number of figures: 10 Number of supplementary Tables: 4 Number of supplementary figures: 7 1 JPET Fast Forward. Published on December 31, 2020 as DOI: 10.1124/jpet.120.000189 This article has not been copyedited and formatted.
    [Show full text]
  • A Review of Unique Opioids and Their Conversions
    A Review of Unique Opioids and Their Conversions Jacqueline Cleary, PharmD, BCACP Assistant Professor Albany College of Pharmacy and Health Sciences Adjunct Professor SAGE College of Nursing DISCLOSURES • Kaleo • Remitigate, LLC OBJECTIVES • Compare and contrast unique pharmacotherapy options for the treatment of chronic pain including: methadone, buprenoprhine, tapentadol, and tramadol • Select methadone, buprenorphine, tapentadol, or tramadol based on patient specific factors • Apply appropriate opioid conversion strategies to unique opioids • Understand opioid overdose risk surrounding opioid conversions and the use of unique opioids UNIQUE OPIOIDS METHADONE, BUPRENORPHINE, TRAMADOL, TAPENTADOL METHADONE My favorite drug because….? METHADONE- INDICATIONS • FDA labeled indications – (1) chronic pain (2) detoxification Oral soluble tablets for suspension NOT indicated for chronic pain treatment • Initial inpatient detoxification of opioids by a licensed trained provider with methadone and supportive care is appropriate • Methadone maintenance provider must have special credentialing and training as required by state Outpatient prescription must be for pain ONLY and say “for pain” on RX • Continuation of methadone maintenance from outside provider while patient is inpatient for another condition is appropriate http://cdn.atforum.com/wp-content/uploads/SAMHSA-2015-Guidelines-for-OTPs.pdf MECHANISM OF ACTION • Potent µ-opioid agonist • NMDA receptor antagonist • Norepinephrine reuptake inhibitor • Serotonin reuptake inhibitor ADVERSE EVENTS
    [Show full text]
  • Hydromorphone
    Hydromorphone WHAT IS HYDROMORPHONE? sedation, and reduced anxiety. It may also cause Hydromorphone belongs to a class of drugs mental clouding, changes in mood, nervousness, called “opioids,” which includes morphine. It and restlessness. It works centrally (in the has an analgesic potency of two to eight times brain) to reduce pain and suppress cough. greater than that of morphine and has a rapid Hydromorphone use is associated with both onset of action. physiological and psychological dependence. WHAT IS ITS ORIGIN? What is its effect on the body? Hydromorphone is legally manufactured and Hydromorphone may cause: distributed in the United States. However, • Constipation, pupillary constriction, urinary retention, users can obtain hydromorphone from nausea, vomiting, respiratory depression, dizziness, forged prescriptions, “doctor-shopping,” impaired coordination, loss of appetite, rash, slow or theft from pharmacies, and from friends and rapid heartbeat, and changes in blood pressure acquaintances. What are its overdose effects? What are the street names? Acute overdose of hydromorphone can produce: Common street names include: Severe respiratory depression, drowsiness • D, Dillies, Dust, Footballs, Juice, and Smack progressing to stupor or coma, lack of skeletal muscle tone, cold and clammy skin, constricted What does it look like? pupils, and reduction in blood pressure and heart Hydromorphone comes in: rate • Tablets, capsules, oral solutions, and injectable Severe overdose may result in death due to formulations respiratory depression. How is it abused? Which drugs cause similar effects? Users may abuse hydromorphone tablets by Drugs that have similar effects include: ingesting them. Injectable solutions, as well as • Heroin, morphine, hydrocodone, fentanyl, and tablets that have been crushed and dissolved oxycodone in a solution may be injected as a substitute for heroin.
    [Show full text]